Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma
Stock Information for Oncternal Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.